These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22029653)

  • 1. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
    Poonia B; Pauza CD
    Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of human peripheral blood γδ T cells using zoledronate.
    Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
    J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-18 activates Vγ9Vδ2
    Murday AS; Chaudhry S; Pauza CD
    Immunology; 2017 Aug; 151(4):385-394. PubMed ID: 28342224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.
    Alexander AA; Maniar A; Cummings JS; Hebbeler AM; Schulze DH; Gastman BR; Pauza CD; Strome SE; Chapoval AI
    Clin Cancer Res; 2008 Jul; 14(13):4232-40. PubMed ID: 18594005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-fibrotic characteristics of Vγ9+ γδ T cells in systemic sclerosis.
    Markovits N; Bendersky A; Loebstein R; Brusel M; Kessler E; Bank I
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):23-29. PubMed ID: 26886502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses.
    Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M
    J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficient IL-2 Produced by Activated CD56
    Xie Z; Zheng J; Wang Y; Li D; Maermaer T; Li Y; Tu J; Xu Q; Liang H; Cai W; Shen T
    Front Immunol; 2019; 10():1647. PubMed ID: 31379845
    [No Abstract]   [Full Text] [Related]  

  • 10. Activation of human γδ T cells by cytosolic interactions of BTN3A1 with soluble phosphoantigens and the cytoskeletal adaptor periplakin.
    Rhodes DA; Chen HC; Price AJ; Keeble AH; Davey MS; James LC; Eberl M; Trowsdale J
    J Immunol; 2015 Mar; 194(5):2390-8. PubMed ID: 25637025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
    Cabillic F; Toutirais O; Lavoué V; de La Pintière CT; Daniel P; Rioux-Leclerc N; Turlin B; Mönkkönen H; Mönkkönen J; Boudjema K; Catros V; Bouet-Toussaint F
    Cancer Immunol Immunother; 2010 Nov; 59(11):1611-9. PubMed ID: 20582413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines.
    Conti L; Casetti R; Cardone M; Varano B; Martino A; Belardelli F; Poccia F; Gessani S
    J Immunol; 2005 Jan; 174(1):252-60. PubMed ID: 15611247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2.
    Li W; Kubo S; Okuda A; Yamamoto H; Ueda H; Tanaka T; Nakamura H; Yamanishi H; Terada N; Okamura H
    J Immunother; 2010 Apr; 33(3):287-96. PubMed ID: 20445349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate].
    Li ZX; Sun LL; Cheng RL; Sun ZW; Ye ZM
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Aug; 28(8):822-4. PubMed ID: 22863589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes.
    Nussbaumer O; Gruenbacher G; Gander H; Thurnher M
    Blood; 2011 Sep; 118(10):2743-51. PubMed ID: 21673342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isopentenyl pyrophosphate secreted from Zoledronate-stimulated myeloma cells, activates the chemotaxis of γδT cells.
    Ashihara E; Munaka T; Kimura S; Nakagawa S; Nakagawa Y; Kanai M; Hirai H; Abe H; Miida T; Yamato S; Shoji S; Maekawa T
    Biochem Biophys Res Commun; 2015 Aug; 463(4):650-5. PubMed ID: 26047704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
    Meraviglia S; Eberl M; Vermijlen D; Todaro M; Buccheri S; Cicero G; La Mendola C; Guggino G; D'Asaro M; Orlando V; Scarpa F; Roberts A; Caccamo N; Stassi G; Dieli F; Hayday AC
    Clin Exp Immunol; 2010 Aug; 161(2):290-7. PubMed ID: 20491785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
    Li Z; Tang J; Sun L; Ye Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
    Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC
    Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures.
    Varesano S; Zocchi MR; Poggi A
    Front Immunol; 2018; 9():998. PubMed ID: 29867975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.